Cynthia Brinson

4.9k citations

36 papers · 1.5k indexed · 1 hit paper · h-index 18

Co-authors: Andrew Cheng Anthony Mills Brian Wynne Edwin DeJesus Michael Aboud Hal Martin Melanie Thompson Kati Vandermeulen
Topics: HIV/AIDS drug development and treatment (34 papers)HIV Research and Treatment (27 papers)HIV/AIDS Research and Interventions (17 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: The Lancet PLoS ONE Clinical Infectious Diseases
Partner nations: United States United Kingdom Germany

In The Last Decade

Cynthia Brinson

33 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers

Countries citing papers authored by Cynthia Brinson

Since Specialization

Citations

This map shows the geographic impact of Cynthia Brinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Brinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Brinson more than expected).

Fields of papers citing papers by Cynthia Brinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cynthia Brinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Brinson. The network helps show where Cynthia Brinson may publish in the future.

Co-authorship network of co-authors of Cynthia Brinson

This figure shows the co-authorship network connecting the top 25 collaborators of Cynthia Brinson. A scholar is included among the top collaborators of Cynthia Brinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cynthia Brinson. Cynthia Brinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study 2025 ·Medicine ·Indira Brar,Peter Ruane,Mezgebe Berhe,Cynthia Brinson,Paul Benson,Keith Henry,Hui Liu,Kristen Andreatta,Jason T. Hindman,Moti Ramgopal	0
2	Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV 2025 ·AIDS Research and Therapy ·Eric S. Daar,Chloe Orkin,Paul E. Sax,Debbie Hagins,Anton Pozniak,Kimberly Workowski,Cynthia Brinson,Juan Tiraboschi,Hui Liu,(unknown),Cal Cohen,Sharline Madera,Jason T. Hindman,Moti Ramgopal	0
3	Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab 2025 ·The Journal of Infectious Diseases ·Joseph J. Eron,Paul Cook,Megha Mehrotra,Hailin Huang,Marina Caskey,(unknown),Linda Gorgos,Laurie A. VanderVeen,(unknown),Sean E Collins,Olayemi Osiyemi,Cynthia Brinson,Edwin DeJesus	1
4	1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine 2020 ·Open Forum Infectious Diseases ·Indira Brar,Peter Ruane,Douglas Ward,Jean‐Michel Molina,Anthony Mills,Mezgebe Berhe,Cynthia Brinson,(unknown),Paul Benson,Keith Henry,Hailin Huang,Kristen Andreatta,Hal Martin	3
5	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial 2019 ·The Lancet HIV ·David A. Wohl,Yazdan Yazdanpanah,Axel Baumgarten,Amanda Clarke,Melanie Thompson,Cynthia Brinson,Debbie Hagins,Moti Ramgopal,Andrea Antinori,Xuelian Wei,Rima Acosta,Sean E Collins,Diana M. Brainard,Hal Martin	116
6	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesbreakdown → 2018 ·The Lancet ·Josep M. Llibre,Chien‐Ching Hung,Cynthia Brinson,Francesco Castelli,Pierre‐Marie Girard,Lesley Kahl,Elizabeth A. Blair,(unknown),Brian Wynne,Kati Vandermeulen,Mark Underwood,(unknown),Martin Gartland,Michael Aboud	243
7	Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide 2018 ·AIDS ·Paul E. Sax,Edwin DeJesus,Gordon Crofoot,Douglas Ward,Paul Benson,Robin Dretler,Anthony Mills,Cynthia Brinson,Xuelian Wei,Sean E Collins,Andrew Cheng	7
8	Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial 2018 ·The Lancet HIV ·Jean‐Michel Molina,Douglas Ward,Indira Brar,Anthony Mills,Hans‐Jürgen Stellbrink,Luís F. López‐Cortés,Peter Ruane,Daniel Podzamczer,Cynthia Brinson,Joseph M. Custodio,Hui Liu,Kristen Andreatta,Hal Martin,Andrew Cheng,Erin Quirk	138
9	Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial 2017 ·The Lancet HIV ·Paul E. Sax,Edwin DeJesus,Gordon Crofoot,Douglas Ward,Paul Benson,Robin Dretler,Anthony Mills,Cynthia Brinson,(unknown),Xuelian Wei,Kirsten White,Andrew Cheng,Hal Martin,Erin Quirk	72
10	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant,Eric S. Daar,François Raffi,Cynthia Brinson,Peter Ruane,Edwin DeJesus,Margaret Johnson,Nathan Clumeck,Olayemi Osiyemi,(unknown),Javier O Morales-Ramirez,Mingjin Yan,Michael E. Abram,Andrew Plummer,Andrew Cheng,Martin S. Rhee	127
11	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial 2015 ·The Lancet Infectious Diseases ·David A. Margolis,Cynthia Brinson,Graham Smith,Jerome De Vente,Debbie Hagins,Joseph J. Eron,Sandy Griffith,M H St Clair,Marita Stevens,Peter Williams,Susan L. Ford,Britt Stancil,(unknown),Krischan J Hudson,Kimberly Y. Smith,William Spreen	157
12	Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment 2015 ·AIDS Care ·(unknown),Calvin Cohen,Benoît Trottier,Stefan Eßer,Don Smith,Bernhard Haas,Cynthia Brinson,Will Garner,Susan K. Chuck,David Thorpe,Shampa De-Oertel	17
13	Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial 2015 ·The Lancet HIV ·Jacob Lalezari,Gulam Latiff,Cynthia Brinson,Juan Echevarría,(unknown),Johannes R. Bogner,Melanie Thompson,Jan Fourie,(unknown),(unknown),Marcelo Martins,(unknown),David Stock,Samit R. Joshi,George J. Hanna,Max Lataillade	50
14	The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects 2015 ·HIV Medicine ·(unknown),Cynthia Brinson,Moti Ramgopal,Robert J. Ryan,Bruce Coate,(unknown),Thomas N. Kakuda,David Anderson	13
15	Safety profile of HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 analysis 2014 ·Journal of the International AIDS Society ·Jacob Lalezari,Gulam Latiff,Cynthia Brinson,Juan Echevarría,(unknown),Johannes R. Bogner,David Stock,Samit R. Joshi,George J. Hanna,Max Lataillade	4
16	Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine 2014 ·The Journal of Infectious Diseases ·Marshall J. Glesby,Wendy Watson,Cynthia Brinson,Richard N. Greenberg,Jacob Lalezari,Daniel J. Skiest,Vani Sundaraiyer,Robert J. Natuk,Alejandra Gurtman,Daniel A. Scott,Emilio A. Emini,William C. Gruber,Beate Schmöele-Thoma	43
17	Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data 2014 ·HIV Clinical Trials ·Anthony Mills,Gordon Crofoot,Roberto Ortiz,Bruce Rashbaum,William Towner,Derek Ward,Cynthia Brinson,Rohan Kulkarni,(unknown),Ramin Ebrahimi,H. Cao,Andrew Cheng,Javier Szwarcberg	17
18	Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens 2013 ·HIV Clinical Trials ·Anthony Mills,Calvin Cohen,Edwin DeJesus,Cynthia Brinson,Scott Williams,Kitty Yale,Srini Ramanathan,Maggie Haitian Wang,Kirsten White,Susan K. Chuck,Andrew Cheng	61
19	SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen 2013 ·Clinical Infectious Diseases ·Rafael Campo,E DeJesus,U. Fritz Bredeek,Keith Henry,Homayoon Khanlou,(unknown),Cynthia Brinson,Paul Benson,(unknown),(unknown),Kirsten White,John F. Flaherty,Todd Fralich,Bill Guyer,David Piontkowsky	36
20	Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jacob Lalezari,Joseph Gathe,Cynthia Brinson,Melanie Thompson,Calvin Cohen,Edwin DeJesus,(unknown),Jerome Ernst,David E. Martin,(unknown)	56

About Cynthia Brinson

Cynthia Brinson is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 36 papers that have together received 1.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (34 papers), HIV Research and Treatment (27 papers) and HIV/AIDS Research and Interventions (17 papers). The work is most often cited by research in Virology (1.0k citations), Infectious Diseases (1.3k citations) and Emergency Medicine (449 citations). Cynthia Brinson has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Andrew Cheng, Anthony Mills, Brian Wynne, Edwin DeJesus, Michael Aboud, Hal Martin, Melanie Thompson, Kati Vandermeulen, Peter Ruane and Debbie Hagins. Their work appears in journals such as The Lancet, PLoS ONE and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact